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Abstract 
Glucocorticoids mediate plethora of actions throughout the human body. Within the 
brain, they modulate aspects of immune system and neuroinflammatory processes, 
interfere with cellular metabolism and viability, interact with systems of 
neurotransmission and regulate neural rhythms. The influence of glucocorticoids 
on memory and emotional behaviour is well known and there is increasing evidence 
for their involvement in many neuropsychiatric pathologies. These effects, which at 
times can be in opposing directions, depend not only on the concentration of 
glucocorticoids but also the duration of their presence, the temporal relationship 
between their fluctuations, the co-influence of other stimuli, and the overall state of 
brain activity. Moreover, they are region- and cell type-specific. The molecular basis 
of such diversity of effects lies on the orchestration of the spatiotemporal interplay 
between glucocorticoid- and mineralocorticoid receptors, and is achieved through 
complex dynamics, mainly mediated via the circadian and ultradian pattern of 
glucocorticoid secretion. More sophisticated methodologies are therefore required 
to better approach the study of these hormones and improve the effectiveness of 
glucocorticoid-based therapeutics. 
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Glucocorticoid pulsatility; ultradian rhythmicity; glucocorticoid-based therapeutics; 
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1. Introduction: glucocorticoids and their clinical significance 
The hypothalamic-pituitary-adrenal (HPA) axis, whose significance in human and 
animal physiology and pathology has been extensively studied for many decades, is 
crucially involved in regulating internal homeostatic mechanisms (many of which 
have a circadian pattern) and coordinating the organisms’ stress responses. Many of 
these phenomena are regulated in man by one of the main end-products of the axis, 
the glucocorticoid (GC) cortisol, and to a lesser extent by corticosterone (which 
additionally constitutes the primary GC type in rodents and other non-human 
primates). These adaptation processes, which are characterized by great diversity, 
involve regulation of developmental (Allen, 1996; Jobe et al., 1998) and metabolic 
pathways (van Rossum and Lamberts, 2004), immune system components (Sorrells 
and Sapolsky, 2007) as well as modulation of human cognition and behaviour.  
 It is well known that GCs are biosynthesized for immediate release in the 
cortical zona fasciculata of the adrenal glands (AGs), and due to their lipophilic 
nature they rapidly diffuse across cell membranes, and are distributed via the 
systemic circulation predominantly - approximately 95% - bound to carrier proteins, 
mainly cortisol binding globin (CBG), and albumin, throughout the body (Lightman 
and Conway-Campbell, 2010) and cleared through liver (bile acids) and kidneys 
(urine) (Glantz et al., 1976). As indicated by these dynamic physicochemical 
properties as well as by more recent studies on endogenous GC dynamics (Hughes 
et al., 2010), GC abundance in the various tissues is primarily regulated by: (i) the 
pattern of their release into the systemic circulation from the adrenal cortex (i.e. the 
mode and integrity of activity of the HPA axis) (Henley et al., 2009a), (ii) the ratio of 
the circulating free to bound form (which is temperature-dependent and together 
with the concentration of CBG determines the availability of the biologically active 
cortisol) (Lentjes and Romijn, 1999), (iii) the tissue-specific existence of enzymes 
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that locally modulate active GC levels (cortisol conversion to inactive cortisone and 
vice versa) (Tomlinson et al., 2004), (iv) the capacity of some tissues (for instance 
the brain) to locally produce/regenerate steroids (Mellon et al., 2001), (v) the activity 
of the P-glycoprotein (PGP) pump across the blood-brain barrier (BBB) and (vi) the 
clearance rate of GCs from liver and kidneys. Processes (i), (ii) and (vi) determine the 
temporally-fluctuating, biologically active systemic GC concentrations.      
The wide spectrum of GC-related biological actions, apart from indicating 
their generic significance in human (and many other animal species’) physiology, 
has been exploited in the field of therapeutics of various disorders; natural or 
synthetic GCs are prescribed/used in several clinical conditions for instance 
inflammatory-oedematous diseases like serious allergies, asthma, serious bacterial 
infections (in combination with antibiotics) and primarily autoimmune disorders 
(Hill et al., 1990; Rhen and Cidlowski, 2005). Other therapeutic indications of GCs 
include conditions like chronic pain (in combination with first line pain killers 
under multi-drug schemes) and neoplastic lesions (again in combination with first 
line anti-neoplastic drugs under multi-drug schemes), as well as adrenal 
insufficiency (replacement therapy) (Crown and Lightman, 2005a).  
Unfortunately, treatment with GCs is often only partial effective and also 
results in adverse effects (Boling, 2004; Crown and Lightman, 2005b). In the field of 
applied clinical neurosciences, GC-based therapeutics present two major challenges; 
the reduction of the neuropsychiatric adverse effects that accompany their high-
dose or long-term use (Klein, 1992; Tavassoli et al., 2008; Ricoux et al., 2013) and 
good scientific evidence for their effectiveness (in neurological cases occasionally 
prescribed). To overcome  these challenges, as well as to further explore possible 
applications of GCs in other neurological processes including diagnosis, 
discrimination between disease subtypes, prognosis, treatment strategies of 
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neuropsychiatric conditions, it is important to conceptualize the multi-level 
regulatory dynamics of GCs in stress regulation and health preservation (Young et 
al., 2004).       
The purpose of this article is to discuss how the new concept of HPA 
pulsatility can provide a methodological and clinically significant advance for our 
understanding of  stress physiology and pathology. We place GCs’ effects on brain's 
functional phenotypes into the context of HPA rhythmicity, as well as   highlight 
some important concepts related to GC neurodynamics in brain physiology and 
pathology.  
 
2.  Inconsistencies in our understanding of GC therapeutics in neurology 
There is a characteristic discrepancy between the preclinical evidence that support 
the utilization of GC-based therapeutics or prognostic markers in various 
pathological cases and the poor results in terms of their efficiency or 
appropriateness when they are actually applied in clinical practice. This is also the 
case in neurological conditions. 
 Association of GCs with stroke evolution and prognosis has for instance 
been highlighted in clinical terms, since cortisol levels were found high during the 
first post-stroke week and such concentrations were associated with higher 
prevalence of systolic blood hypertension and night-time blood hypertension 24-
hours after stroke (Ahmed et al., 2004), and with increased dependency, delirium 
incidences, depression and mortality rates in post-stroke patients (though these 
conclusions are not necessarily independent of stroke severity and thus GC levels 
cannot be used as independent prognostic markers) (Barugh et al., 2014). 
Nevertheless, there is serious scientific confusion on whether GC levels can be used 
for short- and/or long-term prognosis of post-stroke patients, as well as at what 
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stage of the post-stroke clinical evaluation these data should be acquired and 
interpreted (Christensen et al., 2004; Johansson et al., 2000; Marklund et al., 2004). 
There is also a debate on the causal origin of these raised GC concentrations, 
whether there is an alteration between total and free levels of circulating GCs in 
stroke patients, as well as whether there is a correlation between cortisol 
concentrations and its serum carrier protein levels; a recent study estimated an 
inverse and independent relationship between serum albumin and total cortisol 
levels in stroke patients, an observation also independent from stroke severity 
(Dziedzic et al., 2012). 
 Potential therapeutic responses of experimental neurovascular pathologies to 
GCs have been explored over the last 3 decades; GCs attenuate (along with mannitol 
and vitamin E) free radical-mediated peroxidation (Uenohara et al., 1988), increase 
endothelial NO synthase activity via the phosphatidylinositol-4,5-bisphosphate 3-
kinase / protein kinase B pathway, and as such effectively augment regional 
cerebral blood flow and reduce cerebral infarct size (Limbourg et al., 2002), while 
they could also control neuronal cell survival:death rates by indirectly influencing 
more complex neuroinflammatory signalling cascades (Takata et al., 2012). 
Nevertheless, when applied in actual clinical terms, GCs (or at least the clinical 
studies designed to justify their probable utility), fail to highlight any significant 
benefits; randomised trials comparing GC administration within 48 h of acute 
(presumed or definite) stroke onset with placebo or a control group didn’t show any 
difference in the odds of death within one year, while treatment did not appear to 
improve functional outcome in survivors (Sandercock and Soane, 2011). Moreover, 
there is no evidence to support the routine use of GCs in patients with 
haemorrhagic stroke (Feigin et al., 2005). 
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 At another level, recent clinical and pre-clinical research findings indicate a 
possible acute, transient suppression of the HPA axis in traumatic brain injury (TBI), 
(Taylor et al., 2013), which may offer valuable prognostic information (Hannon et 
al., 2013). Moreover, experimental treatment approaches that down-regulate 
neuronal / glial GR signalling exert neuroprotective features (Shi et al., 2014), while 
dexamethasone provides anti-oedematous / BBB-stabilizing effects in animal 
models of TBI (Thal et al., 2013). Lack of GCs (due to experimental adrenalectomy) 
has been shown to exert a similar and additive effect to experimentally-induced TBI 
(fluid percussion injury) on decreasing hippocampal mRNA expression levels of 
neurotrophin-3 (Grundy et al., 2004) and increasing brain-derived neurotrophic 
factor (BDNF) (Grundy et al., 2000), while it prevents the post-TBI-induced increase 
of nerve growth factor (Grundy et al., 2001). Some of these effects are reversed after 
GC substitution. In clinical terms though, evidence strongly discourages the use of 
GCs as part of a therapeutic strategy in acute TBI; a large randomised placebo-
controlled clinical trial (MRC CRASH trial) revealed not only an unchanged mortality 
rate but also an increased risk of death within 2 weeks post-TBI in patients 
receiving methylprednisolone (Roberts et al., 2004).  
 Similar discrepancies have been observed in a number of other conditions, 
like multiple sclerosis and neurodegenerative disorders. For example, increased 
plasma cortisol levels have been associated with more rapid disease progression in 
subjects with Alzheimer-type dementia (AD) (Csernansky et al., 2006). In contrast, a 
large post-mortem neuropathological examination of individuals receiving systemic 
GCs for various medical reasons revealed at least 50% less histological markers of 
AD pathology compared to non-treated subjects (Beeri et al., 2012). Table 1 
summarizes our state of knowledge concerning GCs’ involvement in the 
pathophysiology of a number of neurological conditions. These discrepancies 
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highlight the importance of integrating the complex mechanisms underlying GCs’ 
physiological mode of activity to the strategies for applying GC-based treatments or 
prognostic tools in routine clinical practice (Russell and Lightman, 2014).       
 
3. The concept of HPA pulsatility and its relevance to brain homeostasis 
The contradictory results from preclinical and clinical studies concerning GC roles 
in normal and abnormal brain states introduce serious confounding parameters in 
our efforts to evaluate any possible valuable associations of GCs with clinical 
neurosciences from a therapeutic, prognostic, preventive and / or diagnostic point 
of view. Under which (intrinsic and extrinsic) conditions do GCs promote brain’s 
effective, adaptive, physiological responses and what are the critical factors that 
transform GC influence to an ineffective, pathological insult? Under which terms 
could GCs be of any meaningful clinical use in solving neurological problems? And 
how can we collectively evaluate the sometimes contrasting evidence from different 
experimental or clinical studies trying to approach this field? One crucial step 
towards answering these questions is to place them into the context of HPA (and 
GC) pulsatility.           
 
3.1. Basic regulation of endogenous GC rhythmicity: HPA pulsatility 
Schematically, we can classify the basic regulatory mechanisms that define GC 
pattern of daily systemic fluctuations into two main categories; principal and 
superimposed (Figure 1). GCs are secreted in a circadian rhythm, where the natural 
peak occurs just prior to the active period (in human at about 9 am), followed by a 
gradual fall during the day to reach their nadir levels at roughly midnight. These 
increased GC levels during the circadian peak are thought to mainly arise from an 
augmented corticotrophin-releasing hormone (CRH) drive resulting from reduced 
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inhibitory input from the suprachiasmatic nucleus (SCN) to the paraventricular 
nucleus (PVN) and median eminence (Buckley and Schatzberg, 2005). GCs also 
inhibit the CRH-dependent stimulatory drive by a negative feedback loop at both 
pituitary and hypothalamic levels. Corticolimbic regions are also involved in this 
regulatory process, though it is worth noticing, that they do not directly innervate 
PVN. On the contrary they project via pathways like the bed nucleus of stria 
terminalis (BNST) to a number of basal forebrain, hypothalamic and brainstem cell 
populations that in turn innervate, the medial parvocellular part of this 
hypothalamic region (Herman et al., 2005). The hippocampus is also a target region 
for GC negative feedback, and it in turn exerts an inhibitory effect over HPA activity 
both at the circadian nadir and peak of secretion as well as at the onset and 
termination of the stress response (Jacobson and Sapolsky, 1991). The amygdala 
and prefrontal cortex (PFC) contribute to the regulation of the HPA functional status 
primarily after exposure to stressful conditions, with the amygdala contributing to 
these regulatory processes by enhancing the stress-related GC secretion in a region-
specific manner; central and medial amygdaloidal nuclei being susceptible to 
different stressful stimuli (intrinsic-inflammatory and extrinsic-environmental 
respectively) and contribute to the acute stress responses, while basolateral 
amygdala appears to have a role in the chronic stress integration. Medial PFC, on 
the other hand, has a regulatory role after acute psychogenic or systemic stress 
with an inverse relationship between chronic stress impact and PFC activity. Some 
of these PFC-related feedback mechanisms are characterized by laterality, with the 
right hemisphere being more important (Diorio et al., 1993; Jankord and Herman, 
2008).  
Underlying these mechanisms is a complex dynamic ultradian rhythm 
composed of individual pulses of GC secretion. These pulses vary in amplitude and 
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duration throughout the day, but their origin seems to be the result of a self-
sustaining feedforward and GR-dependent feedback oscillatory activity between the 
anterior pituitary (AP) and AGs - a sub-hypothalamic oscillatory mechanism (Waite 
et al., 2012; Walker et al., 2010; Russell et al., 2010). This results in a 24 h profile of 
circulating endogenous GCs, where pulses of adrenal GC secretion of varying 
amplitude and duration occur periodically, approximately every 60-145 min 
(Lightman et al., 2008; Gavrila et al., 2003), in anticipation of cortisol’s estimated 
half-life (around 90 min) (Rai et al., 2004; Depue et al., 1985). 
Both the circadian and ultradian characteristics can be highly variable, both 
within and between individuals. They depend on genetic, age- and gender-specific 
variations (Van Cauter et al., 1996; Bartels et al., 2003; Spiga et al., 2014), intrinsic 
environmental factors and perceived stress responses that define the temporally 
fluctuating state of activity of feedback and feedforward mechanisms (Lightman et 
al., 2002). Moreover, any underlying neuropsychiatric pathology involving 
corticolimbic areas of the brain (for instance neurovascular or neurodegenerative 
insults), whose integrity is also crucial for effectively modulating stress responses, 
could alter the temporal pattern of GC circulation. A recent study in stroke patients 
with right-sided infarction (Lueken et al., 2009) observed an altered tonic and 
phasic cortisol secretion and a damaged stress response compared to stroke 
patients with left-sided infarction or healthy age-matched controls, concluding that 
the asymmetrical (right hemisphere-coordinated) central regulation of stress system 
could be dysregulated by pathologies affecting these brain areas, leading to 
ineffective protection against disease and external challenges.    
 
3.2. Complex dynamics of GCs reaching the brain  
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Although both the circadian and ultradian rhythms are preserved and synchronized 
within the systemic circulation, central nervous system (CNS) and subcutaneous 
tissue (Qian et al., 2012), the relationship between the patterns by which GCs are 
secreted from AGs and their effect on the modulation of brain physiology or 
pathology are clearly very complex, making the studies on the role of GC pulsatility 
in brain’s physiology very challenging.  
 Schematically, endogenous GC dynamics are regulated at three different 
levels before reaching the level of brain-region specific cellular signalling. Firstly, at 
the level of their pulsatile secretion from AGs, as explained earlier, under the co-
interacting feedforward and feedback mechanisms between and within 
corticolimbic brain areas (as well as possibly other unknown regulatory sites), 
brainstem, hypothalamus, anterior pituitary and adrenal cortex. Secondly, at the 
level of their systemic circulation, where the biologically active portion of GCs is 
distributed to various tissues. At this point, there are two important regulatory 
mechanisms; the amount and binding properties of GC-binding proteins (Henley 
and Lightman, 2011), and the clearance / metabolic rate of the biologically active 
portion of GCs from liver, kidneys and other sites (McKay and Cidlowski, 2003). 
Thirdly, at a brain-specific level, where GC dynamics could be effectively changed 
by processes like BBB penetration, resulting in alteration of the local cortisol to 
corticosterone ratio. Finally, at the brain region-specific cellular level, GC effects are 
determined from (i) the presence of enzymes with the capacity to alter locally the 
active hormonal concentrations, (ii) the differential expression of the two target 
receptors of GCs (mineralocorticoid receptor or MR, and glucocorticoid receptor or 
GR) in the various cell types in that brain region (neuronal and glial populations), 
(iii) other neurotransmitters or neuromodulators that may synchronously co-
influence the same brain area, (iv) intracellular interactions of the GC-sensitive 
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receptors (like the phosphorylation of mitochondrial GR, affected by antidepressant 
fluoxetine) (Adzic et al., 2013) or GC-GR and GC-MR complexes that may regulate 
their signalling efficiency or cellular compartmentalization, and (v) the recruitment 
of other transcriptional co-activators or co-suppressors, as well as interaction with 
epigenetic mechanisms that define transcriptional selectivity (de Kloet et al., 2009; 
Biddie et al., 2012). 
For instance, despite the fact that corticosterone is generally produced in 
much lesser degree compared to cortisol, as reflected by their systemic circulating 
concentrations, with a cortisol to corticosterone ratio (CCR) 93.5 : 6.5 
(Raubenheimer et al., 2006), these dynamics change at a central level. There, PGP, a 
cellular membrane protein found (among others) in the endothelial cells of the BBB 
and responsible for releasing many substances out of the cells, shows a greater 
sensitivity in extruding cortisol rather than corticosterone, i.e. corticosterone is 
preferentially maintained in the human brain (de Kloet et al., 2009). Indeed, the CCR 
of the cerebrospinal fluid is substantially decreased at a ratio of 72 : 28 
(Raubenheimer et al., 2006).            
Another notable aspect of the complex neurodynamics of GCs is the ability 
of the brain to locally produce / regenerate / deactivate neurosteroids (Mellon and 
Griffin, 2002). Despite the fact that the enzymatic activity of Cytochrome P450 21-
hydroxylase (P450c21), the main cytochrome 450 enzyme responsible for 
converting 17-OH-progesterone and progesterone to GC precursors (11-
deoxycortisol and 11-deoxycorticosterone respectively) in AGs, is almost absent 
from CNS tissues (Mellon and Miller, 1989), various brain areas are capable of 
locally altering the GCs levels via (i) cytochrome P450 2D (CYP2D) isoforms (like the 
CYP2D6 isoform in human brain, found in most corticolimbic areas, basal forebrain 
and cerebellum) (Miksys and Tyndale, 2004) which perform the steroid 21-
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hydroxylation (replacing P450c21 lack of activity within the brain) (Kishimoto et al., 
2004), (ii) 11β-hydroxysteroid dehydrogenase (11βHSD), that either increase the 
turnover between active and inactive GCs (isoform 1, found in corticolimbic regions, 
hypothalamic areas, brainstem and cerebellum) or solely degrade active GCs to 
inactive molecules (isoform 2, found in GC-insensitive brain regions like the 
circumventricular organs) (de Kloet et al., 2009), (iii) cytochrome P450 11-beta-
hydroxylase (P450c11β) enzyme (found in neocortex) responsible for converting GC 
precursors to active hormones (cortisol and corticosterone respectively), and (iv) 5a-
reductase (found in hypothalamic areas, corticolimbic regions and 
circumventricular organs), which directs corticosterone precursors to other 
metabolic pathways (Mensah-Nyagan et al., 1999) (Table 2). 
Thus, different brain areas are likely to be exposed to differential 
concentrations of GCs despite the fact that the pattern of systemically oscillating 
GCs levels as defined by the ultradian and circadian rhythm of HPA axis is 
preserved and synchronized throughout the brain. Moreover, the enzyme 11βHSD 
which is differentially expressed in different brain areas can alter the corticosterone 
to cortisol ratio initially established by the higher BBB permeability of 
corticosterone. For instance, circumventricular organs may be exposed to very low 
levels of GCs since they lack the ability to locally produce GCs, they additionally 
contain 11βHSD isoform 2 which degrades GCs to inactive molecules, and 5a-
reductase, which further depletes corticosterone precursors from that brain areas’ 
microenvironment. On the contrary, corticolimbic areas like PFC are able to enhance 
the local presence of GCs by producing and regenerating active GCs (since they 
express enzymatically active forms of CYP2D6, 11βHSD isoform 1 and P450c11β), 
and especially cortisol (due to the presence of 5a-reductase).  
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The ability of particular brain regions to locally enhance (or attenuate) the 
presence of GCs could offer a mechanism for increasing the efficiency of central 
stress response, i.e. to increase the chances that specific stress-related brain areas 
(like PFC) will recruit the (GR-dependent) neuronal mechanisms required for a 
successful behavioural adaptation to stress. Data indicating high degree of cellular 
co-localization between GRs, 11βHSD isoform 1 and P450c11β support this notion 
(Roland et al., 1995; Erdmann et al., 1996).  
From another point of view, the ability of the brain to independently produce 
GC precursors mediated by a different enzyme (CYP2D6) compared to 
corresponding adrenal biosynthesis (P450c21) should probably be considered when 
trying to study the effects of GC deficiency in the brain due to P450c21 deficiency 
(congenital adrenal hyperplasia). In contrast, the drug metyrapone (which crosses 
the BBB if administered systemically) (Stith et al., 1976), used in clinical and 
preclinical GC research, blocks both the adrenal and central synthesis of GCs, 
because it inhibits the action of P450c11β which is a common enzyme in both 
tissues’ steroidogenic pathways. In addition, metyrapone selectively blocks the 
activity of the 11βHSD subtype 1, thereby preventing the regeneration of active 
cortisol (Raven et al., 1995; Sampath-Kumar et al., 1997). Therefore, the 
experimental use of metyrapone is a reasonable strategy to induce cortisol (or/and 
corticosterone) deficiency in the brain (of animals or humans). Though it should be 
noted that metyrapone results to an increase in GC precursors (11-deoxycortisol 
and 11-deoxycorticosterone) which were recently shown to provoke particular 
neuro-modulatory effects (Kaminski et al., 2011).  
Lastly, it is worth mentioning that CYP2D6 enzyme, apart from catalysing the 
synthesis of GC precursors within the brain, also metabolizes a series of CNS-
affecting drugs like opioids, neuroleptics, antidepressants, beta-blockers, drugs of 
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abuse, and neurotoxins (Zanger et al., 2004). Moreover, CYP2D6 brain levels are 
significantly up-regulated in chronic smokers and alcoholics in a cell-type and brain 
region-dependent manner, while genetic variation of CYP2D6 has been associated 
with a number of neuropsychiatric conditions like AD or Parkinson’s disease (PD) 
(Miksys and Tyndale, 2004). All these parameters need to be taken into 
consideration when trying to design a clinical study about the central effects of GCs 
and their contribution in neuropsychiatric pathology. 
 
3.3. Molecular basis of GC actions within the brain 
In accordance with the pluralism of actions that GCs exert in the rest of the body, 
cortisol and corticosterone modify brain’s physiology at multiple levels, primarily 
through binding with MRs and GRs in the cytoplasm, nucleus, mitochondria, 
cellular and mitochondrial membranes. In addition, non-specific GC effects 
(possibly resulting from the physicochemical interactions of GCs with plasma and 
mitochondrial membranes) have also been characterized (Song and Buttgereit, 
2006). 
 We now know that MRs exist in two isoforms within the human brain, as 
alternative splicing between exons 3 and 4 results in an MR mRNA variant encoding 
a receptor protein with four additional amino acids compared to the wild-type MR 
protein (Wickert et al., 2000). The region-specific ratio between the two isoforms 
could be changed under neurological conditions like epilepsy, although from a 
functional point of view these isoforms do not have substantial differences (Wickert 
et al., 2000). Two alternative transcripts of the hippocampal MR have also been 
identified in the rat (Castrén and Damm, 1993), while many more variants have 
been identified in aldosterone target tissues leading to differential responsiveness 
to mineralocorticoids (Pascual-Le Tallec and Lombès, 2005). Integrative research (by 
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exploiting the binding properties of synthetic anti-mineralocorticoid [3H]ZK 91587 
or applying immunohistochemical approaches like in situ hybridization for 
investigating mRNA expression or Western blotting for protein level estimation) in 
many animal species including rats, guinea pigs, dogs and non-human primates like 
squirrel monkeys, indicate that most prominent MR-binding sites and sites of MR 
expression in CNS include hippocampus, lateral septum, amygdala, (Grillo et al., 
1990; Patel et al., 2000) and to a lesser extent cerebral cortex, cerebellum, caudate-
putamen complex, and hypothalamus (Patel et al., 2000; Agarwal et al., 1993) (Table 
3).  
The developmental stage of the individual dynamically alters this profile of 
MR distribution within CNS as MR expression fluctuates between pre- and postnatal 
development in a brain-region specific manner (Matthews, 1998; Diaz et al., 1998), 
while aging is associated with a significant decrease in the expression and 
substrate-binding capacity of MR in these brain areas (Rothuizen et al., 1993); a 
phenomenon that may contribute to the dysregulated feedback activity in the HPA 
axis observed in older individuals (Bohn et al., 1991). Moreover, chronic stress 
seems to down-regulate MR mRNA expression in hippocampus, not only in 
mammals but also in birds (Dickens et al., 2009). Generally, MR expression within 
the rat brain seems to be rapidly, inversely auto-regulated (Chao et al., 1998) 
responding to GCs’ changing levels, as adrenalectomy increases MR protein 
expression within 12 hours while the substitution with corticosterone or 
aldosterone reverses this phenomenon. Moreover, chronic high levels of GCs reduce 
MR protein levels compared to normal controls (Kalman and Spencer, 2002).     
 GRs seem to be more resistant to aging-related alterations in their expression 
or binding capacity within the brain (Rothuizen et al., 1993), though this process 
may region-specific (Perlman et al., 2007). Areas of GR expression include cingulate 
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cortex, hippocampus, PVN and supraoptic nucleus (Matthews, 1998; Kiss et al., 
1988), lateral geniculate, lateral and medial amygdala, thalamus, cerebellum and 
cerebral cortex (Patel et al., 2000) (Table 3). GR expression fluctuates between pre- 
and postnatal development in a brain-region specific manner (Matthews,1998; Diaz 
et al., 1998). Moreover, chronic stress down-regulates GR mRNA expression in the 
PVN, but not in the hippocampus (Dickens et al., 2009). Like MR, the developmental 
stage of the individual and various environmental factors (Meaney et al., 2013) 
dynamically alter this profile of GR expression within CNS, especially when these 
are accompanied with early-life stress (Pryce, 2008). Epigenetic phenomena play an 
important role on this matter (Kino and Chrousos, 2011) and could form a 
molecular basis for developing GR-mediated susceptibility to neuropsychiatric 
pathology (McGowan et al., 2009). Generally, GR expression within the rat brain is 
also inversely correlated, but seems to be less prone to GC changing levels, since GR 
protein levels fluctuate at a lesser degree even after longer periods after 
adrenalectomy (Kalman and Spencer, 2002). Moreover, the underlying regulatory 
mechanism is not only GR-dependent (auto-regulation) but also MR-dependent 
(Chao et al., 1998). 
 The mosaic of GC-sensitive receptors’ distribution throughout the brain is 
not only region-dependent, as described above, but also cell type-dependent. 
Although neurons and glial cells express both kinds of GC-sensitive receptors (Bohn 
et al., 1991), the neuronal-to-glial density ratio of their expression differs between 
brain regions. An extensive study of multiple brain regions of healthy male rats 
based on computer-assisted morphometric and microdensitometric evaluation of 
the GR immunoreactivity (Cintra et al., 1994) revealed important variations between 
them. Areas like the frontal lobe, cingulate cortex, olfactory nuclei, basal forebrain, 
most parts of basal ganglia, thalamus and parietal cortex contain high levels of GR-
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expressing neurons and low GR-expressing glia (neuronal-to-glial density ratio 3-11 
: 1), while areas like PVN and other hypothalamic nuclei, dorsolateral thalamus, the 
most internal layer of the parietal cortex, amygdala, retrosplenial cortex, locus 
coeruleus, lateral parabranchial nucleus and raphe nuclei share a more or less equal 
density of GR-expressing neurons and glia. In only a couple of brain areas (like 
dentate gyrus and solitary tract) the density of GR-expressing glial cells is truly 
greater compared to neurons (neuronal-to-glial density ratio 1 : 3). 
Thus, GCs may control a large number of CNS areas, but this influence is 
differentially mediated by glial cells and neurons in a brain-region dependent 
manner. On the contrary, there seems to be no fundamental variations in the 
manner of intracellular trafficking of GRs among different cellular types in vitro 
(Nishi et al., 1999). The particular interest about glial cells expressing GC-sensitive 
receptors lies on the fact that they represent a highly adaptive cellular part of CNS, 
and are involved in a series of fundamental histopathological processes like neuro-
inflammation and neuro-protection. In this context, it has been highlighted that GCs 
control genomic pathways that could establish glial-specific mechanisms to process 
glutamate and thus protect injured tissue from glutamate-induced neurotoxicity 
(Vardimon et al., 1999). Moreover, it was recently observed that MR-expressing 
astrocyte (a glial cell type) migration is increased to the ischaemic core in 20-min 
middle cerebral artery occlusion mice models, and that blockage of MRs (by 
spironolactone treatment) led to significant suppression of superoxide production 
within the infarct area and to up-regulation in the expression of neuro-protective / 
angiogenic basic fibroblast growth factor and vascular endothelial growth factor 
(Oyamada et al., 2008). At another level the synchronous interplay between 
activated microglia and inflammatory agents under pathological (low) GC levels may 
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contribute to the development of complex phenomena like hyperalgesia (Suarez-
Roca et al., 2014).      
 
3.4. How is GC rhythmicity biologically perceived by the brain?  
There is good evidence that GC rhythmicity is registered at the level of the brain. A 
recent study showed that the pattern of GCs pulses differentially regulates 
glutamatergic neurotransmission and long-term potentiation (LTP, an important 
neuronal mechanism considered to underlie memory formation) induction in 
cultures of hippocampal neurons and dorsal hippocampal slices from rodent brains 
(Sarabdjitsingh et al., 2014), while a previous study has described the phenomenon 
of gene pulsing in rat hippocampus following pulses of GCs (Conway-Campbell et 
al., 2010). 
In the context of GC actions within brain, GC rhythmicity could offer a 
mechanistic, molecular explanation for their diverse effects, because it provides a 
regulatory input which can be “read” differentially by different brain regions 
depending on the amount of GR or MR they express. Moreover, due to different 
affinities of membrane-associated and nuclear MRs and GRs for GCs, the pattern of 
GC rhythmicity will determine which GC- receptors will be activated and their 
duration of activation. This will result in differential cellular effects depending on 
the receptor population, their pattern of activation and the recent history of cellular 
activation.       
 In more detail, current state of knowledge indicates that MRs’ neuronal / 
glial activities may be mediated via either non-transcriptional mechanisms related 
to activation of membrane associated receptors or classic slower genomic pathways 
by activation of cytoplasmic MRs. The former, best described in hippocampal 
neurons, involve rapid (within minutes) effects (Roozendaal et al., 2010; Gutièrrez-
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Mecinas et al., 2011) resulting from activation of receptors in the cell membrane 
with subsequent activation of intracellular phosphorylation cascades. The affinity 
of these membrane-associated receptors is a factor of magnitude less than that for 
to the nuclear MRs (Karst et al., 2005). This difference among affinity properties 
between nuclear- and non-nuclear-located MRs signifies the important role of GC 
pulsatility as a biological mechanism for modulating the initiation and duration of 
corresponding MR-dependent actions in relation to the physiological role that these 
actions exert. Nuclear MRs remain bound to DNA for much longer than GRs and 
circulating GC levels are at any time-point in the ultradian rhythm sufficient to 
preserve a continuous (= tonic) occupation / activation of high-affinity nuclear MRs 
(90% at any time during the day which increases to approximately 100% under acute 
stress conditions) (Reul and de Kloet, 1985), while 10-fold lower-affinity non-
nuclear MRs are activated only during the rising phases and peaks of the GC 
ultradian pulses (depending on the amplitude of each pulse) or under stress, 
leading to increased MRs’ instability and thus proteasome-dependent MR 
degradation (Lightman et al., 2008). 
Like MRs, GRs possess non-nuclear (rapid, non-genomic) and nuclear 
(genomic, delayed) actions. GR-dependent genomic effects may also be 
mitochondrial as well as the well-established nuclear (Scheller et al., 2000; 
Moutsatsou et al., 2001), and GCs can affect brain mitochondrial function in vitro 
(Morin et al., 2000). Nevertheless, GR-dependent effects, rapid or delayed, are 
mediated during periods of high GC concentrations, due to the comparatively low 
affinity of GRs towards cortisol and corticosterone.  
It appears that MRs and GRs have been assigned, in evolutionary terms, to a 
different primary regulatory role, and their CNS-region specificity and mode of 
activation should follow that distinct role; nuclear MRs seem to possess a 
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continuous, “background” activity that stabilises neuronal and glial functions, 
ensuring homeostasis (a process that evolves normally in a long-term basis, which 
is in accordance with the slow, genomic effects of nuclear MRs). Non-nuclear MRs, 
on the contrary, seem to be necessary for coordinating the initial brain response to 
stress (which is acute, and thus in accordance with the fast, non-genomic actions of 
non-nuclear MRs), while GRs at the same time initiate the (sub-acute or even 
chronic) processes responsible for attenuating, and eventually terminating, stress 
responses (re-establishing homeostasis) as well as performing vital neurobehavioral 
adaptations to increase effectiveness towards confronting future threats and 
noxious insults.  
 
3.5. Altered HPA rhythmicity in stressful conditions and human pathology 
In clinical terms, many stressful and pathological states have been correlated with a 
dysregulated 24h ultradian profile of circulating endogenous GCs, indicating an 
altered activity of HPA axis under these conditions, despite the fact that mean 
cortisol or corticotrophin (ACTH) levels do not necessarily differ from normal 
controls (Figure 2). For instance, the study of HPA axis ultradian rhythms in 
premenopausal, viscerally obese women revealed several abnormalities of ACTH 
pulsatile secretion (increased pulse frequency and reduced pulse amplitude) which 
were not accompanied by abnormal mean ACTH concentrations in peripheral blood 
(Pasquali et al., 1998). Another example is obstructive sleep apnoea; in a recent 
study, the deconvolution analysis of secretory pulses in the 24h systemic GC 
profiles of untreated patients revealed longer duration of ACTH and cortisol pulses 
compared to the same patients when they had been successfully treated with 
continuous positive airway pressure therapy (Henley et al., 2009b).   
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Analysis of the 24 h ultradian profile of circulating endogenous GCs could be 
a useful indicator of the aetiology of high or low mean cortisol levels in many 
pathological conditions. In the neuropsychiatric context, neurodegenerative 
disorders like AD and PD, or depression and post-traumatic stress disorder have 
been thoroughly studied. Apart from the disturbed circadian pattern (increased 
waking / morning levels and circadian amplitude) and the increased mean systemic 
cortisol levels observed in AD (Martignoni et al., 1990; Lei, 2010), analysis of the 24 
h ultradian profile of AD (and PD) patients reveals that the hypercortisolemia 
observed in these subjects results from a raised mass of cortisol secreted per burst 
compared to healthy age-matched volunteers without any substantial alterations in 
the cortisol half-life, number of secretory bursts within 24 h, and the mean inter-
secretory pulse interval (Hartmann et al., 1997). On the contrary, the possible 
existence of a dysregulated HPA axis in major depression (Pariante and Lightman, 
2008) leading to hypercortisolemia, or fibromyalgia and chronic fatigue syndrome 
(Cleare, 2004; Calis et al., 2004; Wingenfeld et al., 2008) leading to 
hypocortisolemia, is not accompanied by substantial changes in the ultradian 
pattern of circulating GCs in the majority of particular subgroup of patients, 
although further studies are required (Young et al., 2001; Crofford et al., 2004). The 
co-evaluation of the mean systemic cortisol levels with their ultradian profiles could 
differentiate between different conditions depending on the aetiology (like AD from 
depression or Cushing syndrome) and predict the causal involvement of GCs in the 
initiation and / or progression of neuropsychiatric disorders (Notarianni, 2013). It is 
worth mentioning that in the past, efforts based on the mean GC concentrations 
and their circadian characteristics did not achieve good discrimination between 
depressed patients and patients with other neuropsychiatric pathology 
(schizophrenia, AD and mania) (Christie et al., 1983).   
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4. How does rhythmicity contribute to the diverse and frequently contradicting 
GC effects in the brain?  
GC pulsatility plays a crucial role in the expressed plurality of GCs actions, as it 
offers the biological mechanism to achieve a dissociation between the MR- and the 
GR-dependent actions, as well as an association of them, under differential extent, 
during particular time points or periods (Russell et al., 2015). This association or 
dissociation between GRs’ and MRs’ actions can be realized at various subcellular 
levels. For instance at a nuclear level; MRs and GRs, when both present and 
activated within brain cells, can form heterodimeric complexes with DNA-binding 
and transactivation properties different from those of the respective homodimers 
(Trapp et al., 1994). Furthermore, it can be realized at the level of subcellular 
trafficking of MRs and GRs, where a differential combinatory pattern between them 
has been recently observed in the rat brain after induction of behavioural stress, 
depending on the brain region and the time after stress (Caudal et al., 2004).  
 At a more macroscopic perspective, GC pulsatility discriminates the 
combinatorial pattern of GC-sensitive receptors’ activation between the different 
brain regions. Under physiological conditions, there is a tonic (continuous) GC 
influence in nuclear MR-sensitive brain areas, while only a phasic (periodic) 
influence in non-nuclear MR- and GR-sensitive brain areas, though rapid and 
delayed respectively, creating a mosaic of GC-dependent effects within the brain 
that are receptor type-specific (MR or GR or MR-GR depending on which receptors 
are expressed and activated in a brain-region and cellular type dependent manner) 
and strictly temporally regulated (continuous or time-limited, acute or delayed). 
Under stressful conditions, the spatial mosaic of GC-dependent effects within CNS 
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changes because the increased levels of GCs enhance activation events of non-
nuclear MRs and GRs. 
In relation to GC-sensitive receptor homeostasis, pulsatility offers a self-
limiting method of controlling any membrane MR- or GR-dependent effects (and 
corresponding molecular cascades) that could be damaging in the long-term, but 
desired or necessary in the short-term or under acute stressful conditions. The 
significance of this self-limiting control of GC actions is lost in states characterised 
by a sustained dysregulation of the physiological ultradian pattern, such as chronic 
stress, various neuropsychiatric disorders or chronic treatment with high doses of 
GCs (Barnes and Adcock, 2009). These states result in prolonged high GC levels and 
thus the elimination of the recovery periods / self-limiting control of GR activation 
during the descending phase of the ultradian pulse cycles, leading to brain GC 
resistance (Meijer et al., 2003) followed by GR down-regulation and inductively 
reduced GR-dependent regulatory influences (Makino et al., 1995). For instance, 
rapid GR-dependent negative feedback regulation of ACTH release under basal 
conditions or acute stress (Russell et al., 2010) is reduced in major depression, a 
condition accompanied with an overactive HPA axis (Young et al., 1991). Other 
examples involve the reduction of immune system’s sensitivity to GCs’ 
immunosuppressive effects during chronic psychological stress (Miller et al., 2002), 
or the selective down-regulation of hippocampal GRs under sustained stress in 
rodents and non-human primates (Brooke et al., 1994) or after the experimental 
induction of viral encephalitis in rats (Bener et al., 2007). Additionally, GC 
resistance is thought to contribute to neuropathological mechanisms related to AD 
(another condition accompanied with an upregulated ultradian pattern) (Hartmann 
et al., 1997) such as disrupted axonal transport in cortical areas (Dai et al., 2004).  
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4.1. Neuroinflammation versus immunosuppression  
Considering the importance of the temporal dimension of fluctuating GC 
concentrations within the brain, we can speculate that their short-term increase 
before or after an inflammatory insult may induce different effects. Indeed, acute 
increases of GCs have been shown to reduce certain types of inflammatory 
responses, especially of cytotoxic origin (attenuation of oxidative stress and cellular 
necrosis) if administered concurrently to or after an immune challenge (Nadeau and 
Rivest, 2003), but a major increase in GCs activity prior to an inflammatory insult 
(like exposure to lipopolysaccharide) can actually result in the exact opposite 
[exacerbation of neuronal / glial death, oxidative stress, potentiation of the glial-
mediated inflammatory response by acting as pro-inflammatory chemokines, 
augmentation of interleukin-1β (IL-1β) and tumour necrosis factor-α (TNFα), 
production and enhancement of the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB)-related genomic actions] (Frank et al., 2010; Frank et al., 
2012). Similarly, chronic exposure to high versus physiological GC concentrations 
could also result in varying immunological phenotypes. Indeed, in the long-term, 
under non-stress levels, GCs suppress cytokine (such as IL-1β and TNFα) production, 
nitric oxide (NO) synthesis and transcription factors implicated in inflammatory 
activation (like NFκB), while during chronic stress pro-inflammatory mechanisms 
seem to be up-regulated (Sorrells and Sapolsky, 2007). 
   Given the temporal variation of the neurological effects of GCs and the 
multifactorial nature of the response, it is no surprise that increasing scientific 
evidence from preclinical and clinical studies suggests now that GCs may 
pharmacologically act in unpredictable ways in the context of multiple sclerosis 
patients, because the precise timing, dosage, duration, cellular exposure, and their 
background milieu may differentially affect the progression of the inflammatory 
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response, BBB integrity and cellular viability (Krieger et al., 2014; Blecharz et al., 
2010; Herold and Reichardt, 2013). Similarly, depression-like disruption of off-line 
motor memory consolidation has been observed in these patients under high-doses 
of corticosteroids (Dresler et al., 2010). 
 
4.2. Neurotoxicity versus neuroprotection 
The temporal dimension of the dynamic regulation of GC concentrations, as 
achieved by their endogenous rhythmicity, seems to be crucial in creating optimal 
conditions both for neuronal and glial viability, and in altering their resilience to 
noxious stimuli. Physiological levels of GC concentrations offer a balanced 
environment for neuronal maintenance while both low and high concentrations of 
GCs may deviate this balance to the neurotoxic range (U-shape-like effect) (Abrahám 
et al., 2006). The hippocampus appears to be particularly vulnerable to these 
neurotoxic effects, with CA3 pyramidal neurons being particularly more sensitive 
compared to CA1 pyramidal cells (Levy et al., 1994). Moreover, combination of 
differential GC levels with various noxious stimuli [Aβ-toxicity, hypoxia, N-methyl-D-
aspartate (NMDA)-induced excitotoxicity] leads to either an exacerbation of the 
neurodegenerative effects (when levels of GCs too low or too high) or an 
attenuation of the latter (under moderate corticosteroid levels) in a GC 
concentration-dependent manner (Abrahám et al., 2000). This latter effect has been 
also observed in animal models of cerebral ischemia, where chronic stress prior of 
neurovascular pathology was shown to increase stroke vulnerability, likely through 
GC-related endothelial dysfunction, since this effect was reversed by a GR 
antagonist (mifepristone) (Balkaya et al., 2011). On the contrary, stress or 
corticosterone administration after neurovascular pathology (vasoconstriction-
induced hippocampal ischemia) enhances cognitive recovery in rats (Faraji et al., 
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2009). In accordance with previous data, chronic stress and elevated GC levels 
correlate with Aβ amyloid and tau accumulation (Green et al., 2006) as well as with 
alterations in hippocampal plasticity including dendritic remodelling, neurogenesis 
and LTP (Rothman and Mattson, 2010). On the contrary, administration of 
corticosterone in cortical co-cultures of neurons and astrocytes decreases cytosolic 
Ca2+ levels in a calmodulin- and GR-dependent manner, counteracting glutamatergic 
cytotoxic effects due to calcium overload (Suwanjang et al., 2013). 
 
4.3. Enhancing versus attenuating systems of neurotransmission  
The periodic nature of GC fluctuations within the brain gains further significance if 
we consider that dynamic processes of CNS function, like synaptic and circuit 
plasticity or neurotransmission, are influenced by GCs and need to be strictly 
controlled. For instance, GCs regulate the turnover of dopamine receptors (D1 and 
D2) as well as their sensitivity to their ligands (Biron et al., 1992), and prolonged 
treatment with corticosterone increases mRNA levels of D1 receptors in the 
striatum and nucleus accumbens and selectively up-regulates receptor-ligand 
binding potential in substantia nigra and ventral tegmental area (sites of 
dopaminergic neuronal bodies) in rats (Czyrak et al., 2003). On the other hand, 
metyrapone-induced pharmacological adrenalectomy has the opposite effects 
(Czyrak et al., 1997). Moreover, long-term high levels of GCs under specific 
conditions of genetic susceptibility could exert a long-term, epigenetic control of 
ventral tegmental area-originated dopaminergic neurons (Niwa et al., 2013) as well 
as promote stress-related, dopamine-dependent adaptive changes in 
dopaminoceptive neurons related with emotional and social behavioural 
phenotypes (Barik et al., 2013), contributing to psychopathology. Furthermore, 
disruption of the circadian pattern of GCs’ fluctuations and increased systemic GC 
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levels in rats have been shown to increase dopamine release in the PFC possibly as a 
result of increased synthesis and vesicular storage, providing a mechanistic 
explanation for prefrontal dysfunction in bipolar and other affective disorders 
associated with GC dysrhythmia (Minton et al., 2009) (Figure 3). 
 A second example where the dynamic changes of GC concentrations impose 
rapid effects in a brain region-dependent manner is seen in glutamatergic 
neurotransmission; high levels of GCs increase glutamate release primarily from 
neuronal (and secondary from glial) populations in corticolimbic brain areas by 
increasing the number or the probability of vesicular exocytosis at the presynaptic 
level in a rapid, non-genomic MR-dependent manner (Karst et al., 2005), followed by 
an increased translocation of NMDA and, independently, α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors from intracellular pools to the 
postsynaptic plasma membrane. Moreover, acute stress enhances a NMDA receptor-
independent form of LTP by mobilising calcium-permeable AMPA receptors in a GC-
dependent manner (Popoli et al., 2011). The duration of this MR-dependent up-
regulation of glutamatergic neurotransmission is region-specific, since it’s short-
lasting at the hippocampal level but long-lasting in the basolateral amygdala, where 
subsequent acute stressful insults lead to a GR-dependent down-regulation of 
glutamatergic stimulation (Whitehead et al., 2013). In distinction to this there is a 
brain region-specific adaptation of glutamate release in relation to chronic stress or 
to acute insults after chronic stress, since in some parts of the corticolimbic system 
(i.e. hippocampus) neurotransmission remains constant, while in others (i.e. PFC) it 
gradually decreases. At the same time, there is also a PFC-specific down-regulation 
of both classes of glutamate receptors, an effect related to disrupted receptor 
trafficking and / or altered degradation or synthesis (Karst et al., 2010). Moreover, 
GCs affect glutamate clearance from glial cells through glutamate transporter 
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primarily expressed in these cellular populations; acute stress increases while 
chronic stress decreases glutamate uptake (clearance) and metabolism in the frontal 
cortex and hippocampus through GC-related pathways, although these observations 
need further experimental validation (Karst et al., 2010).  
 A third example where the pattern of GC fluctuations results in differential 
effects involves gamma aminobutyric acid mediated (GABAergic)  
neurotransmission; corticolimbic areas seem more susceptible in this modulatory 
effect, which is characterized by the increase in GABAA-receptor binding affinity at 
both low and high levels of GCs (Majewska et al., 1985; Majewska, 1987; Ong et al., 
1987). High, acute stress-related GC levels result in NO release, which in turn 
stimulates GABA release from the GABAergic terminals in hippocampal inter-
neuronal, inhibitory GABAergic populations; an effect that under chronic stress 
conditions could be proven detrimental for these neuronal networks (Hu et al., 
2010). Daily administration of 1 mg/kg of corticosterone for 3 consecutive weeks in 
rats resulted in a down-regulation of GABAA-receptors’ subunit a2 expression, as well 
as in a corticolimbic area-specific (amygdala vs hippocampus) differential reduction 
of glutamate-to-GABA conversion (Lussier et al., 2013). On the contrary, much 
longer, chronic (1 year) cortisol exposure in primates resulted in significant 
increases in hippocampal calbindin (a Ca2+-binding protein that buffers excess 
calcium), glutamic acid decarboxylase (GABA-synthesizing enzyme) and BDNF; an 
indication that this brain region could strengthen its GABAergic (inhibitory) 
influence under chronic stress conditions, trying to compensate the initial 
glutamate-releasing, excitatory (and the resulting glutamate-related cytotoxic) 
effects of GCs described earlier (McMillan et al., 2004). 
 
4.4. Stress induction and neurobehavioural adaptation 
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In terms of the stress systems’ capacity for mobilisation, GC pulsatility offers a 
mechanism for preserving the ability of the individual to respond to stressful 
situations throughout the day and defines the time points of maximal effectiveness. 
The ascending phase of each GC pulse cycle (which gradually induces activation of 
membrane associated MRs and GRs) constitutes a preparatory stage for initiating an 
effective stress response (if required), while the descending phase of the pulse cycle 
is less prone to support an equally effective stress response, serving probably as a 
recovery period before the ascending phase of the next GC pulse. Indeed, research 
work has highlighted that exposure to noise stress induces a stronger ACTH release 
and behavioural reactivity when animals were stressed during the rising phase of an 
ultradian corticosterone pulse compared with animals exposed to the same stressor 
during the falling phase (Sarabdjitsingh et al., 2010). The actual mobilization, 
though, of a stress response requires the synergy of the “GC background” (defined 
by the phase of the pulse cycle at the moment of the stressful stimulus’ occurrence) 
with a plethora of other neuro-hormonal phenomena such as the release of 
hypothalamic CRH (leading to an increase in the GC secretion) and other 
neuropeptides, the activation of the peripheral, sympathetic nervous system 
(adjusting the entire body’s metabolic demands for confronting the stressful insult) 
as well as the central noradrenergic, dopaminergic and serotoninergic circuits 
(which coordinate the behavioural adaptations during and after the stressful event) 
(Joëls et al., 2009). 
The synchronous co-influence of GCs and other stress-coordinated neuro-
hormonal stimuli within specific brain regions provides a mechanism for 
discrimination between the effects of high corticosteroid levels under baseline 
conditions (for instance during the peaks of the ultradian pulses) and stress. Such 
phenomena has been shown to mediate stress-dependent cognitive processes; for 
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example, synergy between noradrenergic system and GCs leads to a strong 
deactivation of PFC areas during emotional encoding in human (van Stegeren et al., 
2010), while preclinical research has highlighted the crucial role of GCs-
noradrenaline regulatory interactions at multiple levels: (i) at the level of basolateral 
amygdala for enhancing emotionally arousing-related memory consolidation 
(Roozendaal et al., 2006) and social behaviour (Roozendaal et al., 1996; Schwabe et 
al., 2010) by enhancing synaptic plasticity (Sarabdjitsingh et al., 2012), (ii) at the 
hippocampal level, where they alter the functional contribution of AMPA receptors 
to glutamatergic neurotransmission (Zhou et al., 2012), or (iii) at the level of 
hypothalamus, where they modulate feeding behaviour (Leibowitz et al., 1984; 
Jhanwar-Uniyal and Leibowitz, 1986; Roland et al., 1986). Collectively, these 
combined effects promote behavioural adaptation to stressful situations (Krugers et 
al., 2012). 
 
5. Epilogue 
GC rhythmicity which emerges as a natural consequence of the 
feedforward:feedback interactions between the pituitary and adrenal cortex, results 
in many physiological consequences (Table 4). Systemic GC concentrations should 
be perceived and studied not as a binary system (high versus low), but as a 
continuously changing system, whose impact on the brain depends on individual 
characteristics, the system’s endogenous rhythms, brain region and cell type, as 
well as the temporal relationship between glucocorticoid fluctuations and 
application of other endogenous or exogenous, physiological or pathological 
stimuli. Any discrepancies about glucocorticoid effects on the brain or when trying 
to utilise them in the therapeutic or other clinical context become easier to 
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comprehend if we consider the homeostatic importance of these continuous, 
dynamic, ultradian fluctuations. 
A deeper understanding of HPA axis activity, its modulatory effects, and how 
physiological activity changes upon pathological activation, is a prerequisite for 
developing a rational system of glucocorticoid therapeutics. The defining, multi-
level dependency of human body homeostasis from GC homeostasis has been long 
ago recognised (Chrousos and Gold, 1992), as has the effect of disruption of GC 
homeostasis on biological processes including the developmental (in utero) 
determination of longevity, effective adaptation to environment and susceptibility 
to disease (Reynolds, 2013; Ter Wolbeek et al., 2015). Pulsatility offers a novel 
approach to understanding the diverse actions of GCs on neuroinflammatory 
responses, neuronal and glial metabolic properties and survival, CNS circuit 
dynamics, and behavioural and cognitive phenotypes. Furthermore it can provide 
insight into the reasons for the contradictory data found in studies of GC-brain 
interactions, justify the impressively wide range of the central GC actions, as well as 
promote a strong impetus for further studies into the therapeutic role of GCs in 
neuropsychiatric disorders. In addition, a better understanding of GCs’ 
physiological and pathological responses in the brain could even allow the creation 
of algorithms to predict responses based on predefined biological and clinical 
parameters.   
 
List of abbreviations 
11βHSD: 11β-hydroxysteroid dehydrogenase 
ACTH: corticotrophin 
AD: Alzheimer disease 
AGs: adrenal glands 
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AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AP: anterior pituitary 
BBB: blood-brain barrier 
BDNF: brain-derived neurotrophic factor 
BNST: bed nucleus of stria terminalis  
CBG: cortisol binding globin  
CCR: cortisol to corticosterone ratio 
CNS: central nervous system 
CRH: corticotrophin-releasing hormone 
CYP2D: cytochrome P450 2D 
D1: dopamine receptor type 1 
D2: dopamine receptor type 2 
GABA: gamma-aminobutyric acid 
GABAA: GABA receptor type A 
GC: glucocorticoid 
GR: glucocorticoid receptor 
HPA: hypothalamic-pituitary-adrenal (axis) 
IL-1β: interleukin 1beta 
LTP: long term potentiation 
MR: mineralocorticoid receptor 
NFκB: kappa-light-chain-enhancer of activated B cells nuclear factor 
NO: nitric oxide 
P450c11β: cytochrome P450 11-beta-hydroxylase 
P450c21: cytochrome P450 21-hydroxylase 
PD: Parkinson disease 
PFC: prefrontal cortex 
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PGP: P-glycoprotein 
PVN: paraventricular nucleus 
TBI: traumatic brain injury   
TNFα: tumour necrosis factor alpha  
SCN: suprachiasmatic nucleus 
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Legends to the Figures 
 
Figure 1: Hypothalamic-pituitary-adrenal (HPA) axis and its interactions with 
brain regions under physiological or stressful conditions. Glucocorticoids (GCs) 
are secreted from adrenal glands (AGs) into the systemic circulation in a pulsatile 
manner as the result of a self-sustained interplay between AGs and the anterior 
pituitary (AP). The characteristics of that interplay involve (i) a positive feedforward 
stimulation from AP to AGs (mediated via the hormone corticotrophin or ACTH) 
and (ii) a delayed negative feedback stimulation from AGs to AP (mediated via the 
GCs themselves). Certain hypothalamic nuclei, like the paraventricular nucleus 
(PVN), are able to modify the circadian characteristics of the GC pulses by secreting 
corticotrophin-releasing hormone (CRH), which promotes ACTH secretion at the 
pituitary level. At a supra-pituitary level, PVN constitutes a key neuroanatomical 
location being able to dynamically alter the mode of GC secretion (via CRH 
secretion) in response to a number of different stimuli, like: (i) inhibitory feedback 
signals from circulating GCs, (ii) excitatory input from autonomic nervous system 
due to physical challenge, and (iii) inhibitory input from other hypothalamic nuclei 
and bed nucleus of stria terminalis (BNST) in response to psychological stress or 
pathological insults. The latter are encoded via complex interactions between 
corticolimbic regions of the brain, like amygdala, hippocampus and prefrontal 
cortex (PFC). These interactions, when dysregulated as a result of neuropsychiatric 
pathology, may affect the mode of HPA axis functioning and vice versa, a 
dysrhythmic HPA axis may facilitate the development of neuropsychiatric 
pathology. Green arrows: stimulatory effect, Red arrows: inhibitory effects, Grey 
arrows: mixed effect 
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Figure 2: 24-h plasma cortisol and/or corticotrophin (ACTH) profiles. Theoretical 
diagrams presenting normal 24-h plasma cortisol or/and ACTH profiles (dark blue) 
in comparison to other corresponding pathological profiles (light blue). (A): 
Abnormal cortisol profile is characterized by pulses of cortisol of increased 
amplitude, without any alterations in the overall number of pulses or their 
duration. Such a profile has been reported in patients with Alzheimer’s or 
Parkinson disease, and leads to increased mean cortisol concentrations. (B): 
Abnormal ACTH profile is characterized by pulses of ACTH of decreased amplitude 
combined with an increase in the daily number of pulses. Such a profile has been 
observed in premenopausal, viscerally obese women. Mean cortisol concentrations 
may be normal. (C): Abnormal ACTH and cortisol profiles are characterized by 
pulses of longer duration. Such a profile has been reported in patients with 
obstructive sleep apnoea not treated with continuous positive airway pressure 
therapy. Mean cortisol concentrations could be increased. 
 
Figure 3: Glucocorticoids and psychopathology. Reciprocal dysregulated 
interactions between various systems of neurotransmission, for instance the 
dopaminergic and/or the serotoninergic systems, with the hypothalamic-pituitary-
adrenal (HPA) axis, alters susceptibility to different psychiatric phenotypes 
including depressive behaviour, addiction, psychosis, anxiety disorders, 
antisocial/aggressive behaviour and post-traumatic stress disorder (PTSD). 
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Tables 
 
Table 1: Glucocorticoid (GC) involvement in neuropathology.  
GABA: gamma-aminobutyric Acid, HPA: hypothalamic-pituitary-adrenal, MS: 
multiple sclerosis TBI: traumatic brain injury 
Multiple 
sclerosis  
 GC-based therapeutics for anti-inflammatory control in disease relapse 
management  
 dysregulated HPA axis in MS with affective symptomatology  
Stroke  stress-related GC-mediated signaling implicated in atherosclerotic 
development and endothelial dysfunction 
 stress and up-regulation of HPA axis differentially affect stroke prognosis 
depending on the time of onset and duration 
 GC-mediated reduction of oxidative stress and increase in penumbral rescue 
rate  
 nevertheless, application of GCs, under current therapeutic schemes, does not 
attribute any benefit      
Traumatic 
brain 
injury  
 acute, transient post-TBI HPA axis suppression.  
 GC effects may counteract some of the damaging consequences of TBI, like 
oedema, blood-brain-barrier dysfunction and disruption of growth factors’ 
homeostasis in certain brain regions.  
 nevertheless, application of GCs is, under current therapeutic schemes, not 
beneficial or even harmful.       
Alzheimer 
disease  
 hyperactive HPA axis  
 stress-related GC-mediated signaling is involved in amyloidogenesis, tau 
hyper-phosphorylation and impaired hippocampal plasticity.   
Parkinson 
disease  
 hyperactive HPA axis.  
 stress-related GC-mediated signaling is associated with inflammatory 
dopaminergic neurodegeneration.  
Non-
specific 
dementia 
 side effect of long-term and/or high-dose treatment with GCs.  
 GCs interfere with glutamatergic, GABAergic, noradrenergic and cholinergic 
systems of neurotransmission, which are important in coordinating memory 
formation and consolidation, as well as glutamate-related cytotoxicity.   
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Table 2: Neuroanatomical distribution of enzymes involved in steroidogenic pathways. 
11βHSD: 11β-hydroxysteroid dehydrogenase, CYP2D: cytochrome P450 2D, P-45011β: 
cytochrome P450 11-beta-hydroxylase.   
BRAIN REGIONS 5a-reductase 11βHSD P-45011β CYP2D 
Brainstem  +   
Hypothalamus + +   
Thalamus +    
Cerebellum  +  + 
Striatum    + 
Amygdala  +   
Hippocampus + +  + 
Occipital lobe    + 
Nucleus accumbens    + 
Neocortex + + + + 
Circumventricular organs + +   
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Table 3: Spatial pattern of distribution of glucocorticoid-sensitive receptors in the brain.  
GR: glucocorticoid receptor, MR: mineralocorticoid receptor  
BRAIN REGIONS MR dominance Comparable quantities GR dominance  
Dorsomedial PFC     
Cingulate Cortex     
Hippocampus     
Rest of PFC     
Rest of Cerebral Cortex     
Lateral Geniculate     
Nucleus accumbens     
Basal Ganglia     
Amygdala     
Thalamus     
Cerebellum     
Hypothalamus     
 
 
 
Table 4: Role of glucocorticoid (GC) pulsatility in brain function. 
GR: glucocorticoid receptor, MR: mineralocorticoid receptor 
1. Temporal association/dissociation between MR- and GR-coordinated actions 
2. Spatial mosaic of GC-dependent effects depending on the specific brain region and cell 
type 
3. Importance for optimal cognitive and emotional function 
4. Self-limiting control of damaging long-term GR-coordinated actions  
5. Sustaining capacity of the stress system to effectively respond to insults throughout the 
day 
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Figure 3 
 
